Response Genetics, Inc. Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014
April 31, 2015 at 08:05 pm EDT
Share
Response Genetics Inc. announced unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net revenue of $4,079,167 against $4,770,977 a year ago. Operating loss was $3,067,785 against $3,151,621 a year ago. Net loss was $3,412,062 against $3,180,931 a year ago. Basic and diluted loss per share was $0.09 against $0.09 a year ago.
For the year, the company reported net revenue of $16,720,327 against $19,801,359 a year ago. Operating loss was $13,007,588 against $7,945,805 a year ago. Net loss was $13,699,362 against $8,020,515 a year ago. Basic and diluted loss per share was $0.35 against $0.24 a year ago. The company's net loss increased primarily due to the nature and timing of the decrease in pharmaceutical revenues and increased expenses.
Response Genetics, Inc. is a life science company. The Company is engaged in the research, development, marketing and sale of pharmacogenomic tests for use in the treatment of cancer. To generate pharmacogenomic information from patient specimens for these tests, the Company uses its own methods for the extraction and analysis of nucleic acids and accessing the genetic information available from each patient sample. The Company's platforms include analysis of single biomarkers using the polymerase chain reaction method, as well as gene interrogation using microarray methods and fluorescence in situ hybridization (FISH) from paraffin or frozen tissue specimens. The Company is engaged in selling ResponseDX diagnostic testing products. The Company provides pharmacogenomic clinical trial testing services to pharmaceutical companies in the United States, Asia and Europe.
RESPONSE GENETICS, INC 